Future therapeutics aimed at blocking PLXNB2 and SEMA4C/4A interactions can potentially serve as targeting strategies in breast cancer, especially TNBC and complement existing treatments, such as pembrolizumab69–71, Sacituzumab72,73, and Palbociclib74 for improved outcomes. Here, SEMA4C is linked to breast carcinoma.